Tempest Therapeutics Investor Relations Material
Latest events
Study Update
Tempest Therapeutics
Q2 2025
11 Aug, 2025
Q1 2025
13 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Tempest Therapeutics Inc
Access all reports
Tempest Therapeutics Inc. is a clinical-stage biotechnology firm dedicated to developing small molecule therapeutics aimed at treating cancer. Their approach involves mechanisms that not only directly kill tumor cells but also activate tumor-specific immunity. The company is headquartered in Brisbane, California, and its shares are listed on the NASDAQ.
Key slides for Tempest Therapeutics Inc
Corporate Presentation
Tempest Therapeutics Inc
Corporate Presentation
Tempest Therapeutics Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
TPST
Country
🇺🇸 United States